In general, the interaction between NF-κB signaling and the development of myocardial fibrosis in HF suggests that targeting this important pathway could lead to the creation of a new therapeutic strategy aimed at reducing cardiac fibrosis and improving cardiac function in patients with HF. Here, NFKB1 is linked to Myocardial fibrosis.